Publications by authors named "L Martin-Carbonero"
Introduction: There are few validated commercially available HIV-2 assays for the measurement of viral load. Our aim was to compare three commercial assays for the quantification of HIV-2 viral load in plasma of patients with HIV-2 infection from our hospital.
Material And Methods: We conducted a retrospective study at our tertiary-care hospital, analyzing samples from patients with known HIV-2 infection collected between 2022 and 2023.
Article Synopsis
- The study assessed the effects of hepatic steatosis-insulin resistance (HS-IR) and liver fibrosis (LF) on the development of type 2 diabetes mellitus (DM2) using specific measures (TyG and FIB-4).
- The incidence rates of DM2 were recorded as 12.9 per 1000 person-years for HS-IR and 9.8 per 1000 for LF.
- There was a significant reduction in the prevalence of HS-IR at both 12 and 24 months when treated with TDF combined with either 3TC or FTC and RPV, indicating beneficial treatment outcomes.
Purpose: Globally, it is estimated that 1.0 million individuals are newly infected by Hepatitis C virus (HCV) every year, and nearly 50 million people live with a chronic infection, according to World Health Organization. To overcome underdiagnosis of HCV infection among hard-to-reach populations, it is essential to develop new rapid and easy-to-use molecular diagnostic systems.
View Article and Find Full Text PDFArticle Synopsis
- About 10% of people with HIV experience low-level viremia (LLV) despite antiretroviral therapy, yet the causes and impacts of this condition remain largely unknown, especially within specific viral load ranges and modern treatment methods.
- The study observed 81 participants, comparing those with LLV to those with suppressed viremia and non-HIV controls, focusing on immune response characteristics and inflammation markers through advanced flow cytometry and immunoassays.
- Findings indicated that LLV individuals exhibit greater T-cell activation and senescence, along with a decline in certain immune cell types, which could impair their ability to control HIV and harm long-term immune memory.
Liver fibrosis is a key determinant of the progression of metabolic dysfunction-associated steatotic liver disease (MASLD). Its increasing prevalence and a lack of effective treatments make it a major health problem worldwide, particularly in people living with HIV, among whom the prevalence of advanced fibrosis is higher. We have published preclinical data showing that Rilpivirine (RPV), a widely used anti-HIV drug, selectively triggers hepatic stellate cell (HSC) inactivation and apoptosis through signal transducer and activator of transcription (STAT)1-mediated pathways, effects that clearly attenuate liver fibrosis and promote regeneration.
View Article and Find Full Text PDF